Shots:
- Olympus has entered into a definitive agreement to acquire BioProtect, incl. its Balloon Spacer system designed to protect healthy tissue during prostate cancer radiotherapy
- As per the agreement, Olympus will acquire BioProtect in a deal valued at ~$270M, with certain amounts held in escrow subject to uninterrupted business operations; closing is expected by the end of Q2’26
- The acquisition expands Olympus’s presence in GI & urological care, combining BioProtect’s spacing technology with Olympus’ global commercial reach to expand access to prostate cancer treatment solutions
Ref: PRnewswire | Image: BioProtect | Press Release
Related News: Medtronic Plans to Acquire SPR Therapeutics, Strengthening its Pain Portfolio
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
